RT Journal
A1 Kuehn BM
T1 Fda panel: Ban 2 popular asthma drugs
JF JAMA
JO JAMA
YR 2009
FD January 28
VO 301
IS 4
SP 365
OP 366
DO 10.1001/jama.2008.991
UL http://dx.doi.org/10.1001/jama.2008.991
AB 
The panel was charged with assessing the risks and benefits of certain asthma treatments, specifically the long-acting β-agonist (LABA) drugs formoterol and salmeterol and combination products containing both a LABA and an inhaled corticosteroid (formoterol plus budesonide and salmeterol plus fluticasone). Previously, the FDA’s Office of Drug Safety and the agency’s pulmonary and allergy drug products division had made contradictory recommendations concerning LABAs.